Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study

Vitiligo

Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study

J Am Acad Dermatol

Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos LL, Erskine L, Wagya K, Blauvelt A

doi: 10.1016/j.jaad.2025.06.027

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Atopic Dermatitis

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Kridin S, Mayer E, Sawaed W, Ludwig RJ

doi: 10.1111/jdv.20864

Atopic Dermatitis

Harmonizing Measurement of Eczema Control- Mapping Scores Between the Atopic Dermatitis Control Tool and The Recap of Atopic Eczema Instrument

Br J Dermatol

Gillespie J, Bash GN, Jacobson ME, Latour E, Simpson EL

doi: 10.1093/bjd/ljaf167

Rheumatoid Arthritis

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Rheumatology (Oxford)

Hiramatsu Y, Kotani T, Nakamura E, Yoshikawa A, Hashimoto M, Onishi A, Murata K, Yamamoto N, Murakami K, Hirano T, Maeda Y, Ebina K, Sendo S, Son Y, Amuro H, Hara R, Katayama M, Yamamoto W, Takeuchi T

doi: 10.1093/rheumatology/keaf558

Rheumatoid Arthritis

Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers

Arthritis Res Ther

Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Shiga T, Yamazawa H, Ishimura K, Morimoto Y, Fukuda R, Kinoshita K

doi: 10.1186/s13075-025-03672-y

Rheumatoid Arthritis

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

J Clin Med

Lasa-Teja C, Fernández-Cabero JJ, Sánchez-Bilbao L, Loricera J, González-Mazón I, Álvarez-Reguera C, Herrero-Morant A, Corrales-Martínez A, Portilla-González V, Martín-Varillas JL, Pérez-Garrido L, Santos-Gómez M, López-Hoyos M, Blanco R

doi: 10.3390/jcm15010278

Related content

Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

Harmonizing Measurement of Eczema Control- Mapping Scores Between the Atopic Dermatitis Control Tool and The Recap of Atopic Eczema Instrument

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study

Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study